In addition, from a therapeutic perspective, continuous peripheral administration of nesfatin-1 would be the preferred mode of delivery for the treatment for metabolic diseases, especially obesity. Here, NUCB2 is linked to obesity due to melanocortin 4 receptor deficiency.